Zobrazeno 1 - 10
of 189
pro vyhledávání: '"Nora, Horick"'
Autor:
Jeffrey A Meyerhardt, Sunil Kumar, Jessica A Zerillo, Aparna Parikh, James M Cleary, Scott Rodig, Benjamin Schlechter, Kimmie Ng, Stephanie K Dougan, Nora Horick, Glenn J Hanna, Andrew L Coveler, Anuj K Patel, Nadine J McCleary, Douglas A Rubinson, Jeffrey W Clark, Kent Mouw, Kathleen Pfaff, Thomas A Abrams, Matthew B Yurgelun, Eliezer M Van Allen, S Jennifer Wang, Leah H Biller, Harshabad Singh, Emma L Welsh, Brandon M Huffman, Lestat R Ali, Megan T Hoffman, Katherine A Metayer, Shayla Murray, Alexandra Bird, Jennifer A Chan, Wolfram Goessling, Jeffrey S Wisch, Brendan Reardon, Robert J Mayer, Catherine Del Vecchio Fitz, Charlotte Kuperwasser
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous cell carcinoma and biomarkers predictive of response are greatly needed.Methods This multicenter phase
Externí odkaz:
https://doaj.org/article/3355b66d86a3433d9514838bcb4205a5
Autor:
Emily M. Hayden, Pierre Borczuk, Sayon Dutta, Michael R. Filbin, Shan W. Liu, Benjamin A. White, Eleonore Kugener, Blair A. Parry, Nora Horick, Kori S. Zachrison
Publikováno v:
Journal of the American College of Emergency Physicians Open, Vol 4, Iss 3, Pp n/a-n/a (2023)
Abstract Objective There is limited evidence on the reliability of video‐based physical examinations. We aimed to evaluate the safety of a remote physician‐directed abdominal examination using tablet‐based video. Methods This was a prospective
Externí odkaz:
https://doaj.org/article/4b31e82329f94c5c8dce0be1fdfdf930
Autor:
Caron Jacobson, Matthew J Frigault, Nora Horick, Areej R El-Jawahri, Kevin Lindell, Dustin J Rabideau, P Connor Johnson, Alisha Yi, Mahmoud R Gaballa, Gabriel D DePinho
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Chimeric antigen receptor (CAR) T-cell therapy recipients may receive bridging therapy while awaiting product manufacturing to control disease. Yet, data are lacking regarding the impact of bridging therapy use on clinical outcomes.Methods
Externí odkaz:
https://doaj.org/article/e2c29abb29b847ad9400146f5ffa24b3
Autor:
Marc Wehrli, Marcela V Maus, Matthew J Frigault, Mark B Leick, Nora Horick, Paul O'Donnell, Kathleen Gallagher, Yi-Bin Chen, Steven L McAfee, Areej R El-Jawahri, Zachariah DeFilipp, Thomas Spitzer, Bimal Dey, Daniella Cook, Michael Trailor, Kevin Lindell
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/10c1819e606a475e82bdbd71febdb0e1
Autor:
Steven J. Isakoff, Maya R. Said, Agnes H. Kwak, Eva Glieberman, Emily A. O’Rourke, Amanda Stroiney, Laura M. Spring, Beverly Moy, Aditya Bardia, Nora Horick, Jeffrey M. Peppercorn
Publikováno v:
Breast Cancer Research and Treatment. 199:501-509
Purpose Patients with breast cancer (BC) face complex medical information and decisions. The Outcomes4Me mobile app provides evidence-based BC education, symptom management tracking and clinical trial matching. This study sought to evaluate the feasi
Autor:
Neelima Vidula, Senthil Damodaran, Erica L. Blouch, Nora Horick, Nathan Royce Ruffle-Deignan, Manali Bhave, Ami N. Shah, Leticia Varella, Vandana Abramson, Joseph Sparano, Leif Ellisen, Ishraq Alim, Harry Ostrer, Hope Rugo, Aditya Bardia
Publikováno v:
Cancer Research. 83:OT1-11
Background: PARP inhibitors are currently approved for the treatment of germline BRCA1/2 mutant metastatic breast cancer (MBC), which accounts for 5-10% of breast cancer. We hypothesize that a PARP inhibitor may also have efficacy in somatic BRCA1/2
Autor:
Kimberly Perez, Anna M Chiarella, James M Cleary, Nora Horick, Colin Weekes, Thomas Abrams, Lawrence Blaszkowsky, Peter Enzinger, Marios Giannakis, Lipika Goyal, Jeffrey A Meyerhardt, Douglas Rubinson, Matthew B Yurgelun, Wolfram Goessling, Bruce J Giantonio, Lauren Brais, Victoria Germon, Danielle Stonely, Srivatsan Raghavan, Basil Bakir, Koushik Das, Jason R Pitarresi, Andrew J Aguirre, Michael Needle, Anil K Rustgi, Brian M Wolpin
Publikováno v:
The Oncologist. 28:425-432
Background In preclinical pancreatic ductal adenocarcinoma (PDAC) models, inhibition of hepatocyte growth factor (HGF) signaling using ficlatuzumab, a recombinant humanized anti-HGF antibody, and gemcitabine reduced tumor burden. Methods Patients wit
Autor:
Stephanie L. Santoro, Nicole T. Baumer, Michelle Cornacchia, Catherine Franklin, Sarah J. Hart, Kelsey Haugen, Margaret A. Hojlo, Nora Horick, Priya S. Kishnani, Kavita Krell, Andrew McCormick, Anna L. Milliken, Nicolas M. Oreskovic, Katherine G. Pawlowski, Sabrina Sargado, Amy Torres, Diletta Valentini, Kishore Vellody, Brian G. Skotko
Publikováno v:
American Journal of Medical Genetics Part A. 191:1470-1473
Autor:
Stephanie L. Santoro, Nicole T. Baumer, Michelle Cornacchia, Catherine Franklin, Sarah J. Hart, Kelsey Haugen, Margaret A. Hojlo, Nora Horick, Priya S. Kishnani, Kavita Krell, Andrew McCormick, Anna L. Milliken, Nicolas M. Oreskovic, Katherine G. Pawlowski, Sabrina Sargado, Amy Torres, Diletta Valentini, Kishore Vellody, Brian G. Skotko
Publikováno v:
American Journal of Medical Genetics Part A. 188:3049-3062
Research to guide clinicians in the management of the devastating regression which can affect adolescents and young adults with Down syndrome is limited. A multi-site, international, longitudinal cohort of individuals with a clinical diagnosis of Une
Autor:
Kristen Spencer, Leontios Pappas, Islam Baiev, Jordan Maurer, Andrea Grace Bocobo, Karen Zhang, Apurva Jain, Anaemy Danner De Armas, Stephanie Reyes, Tri Minh Le, Osama E Rahma, Jennifer Stanton, Thomas T DeLeon, Marc Roth, Mary Linton B Peters, Andrew X Zhu, Jochen K Lennerz, A John Iafrate, Kylie Boyhen, Christine VanCott, Lewis R Roberts, Stacie Lindsey, Nora Horick, Laura Williams Goff, Kabir Mody, Mitesh J Borad, Rachna T Shroff, Robin Kate Kelley, Milind M Javle, Lipika Goyal
Publikováno v:
JNCI: Journal of the National Cancer Institute.
Background Treatment patterns for intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) differ, but limited studies exist comparing them. This study examines differences in molecular profiling rates and treatment patterns in